At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Market Closed 02-20 16:08:38
6.650
+0.120
+1.84%
High6.700Low6.520Vol21.00M
Open6.530D1 Closing6.530Amplitude2.76%
Mkt Cap124.76BTradable Cap124.76BTotal Shares18.76B
T/O139.35MT/O Rate0.11%Tradable Shares18.76B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Sino Biopharmaceutical Stock Rises 1.8% in Hong Kong
Dow Jones  ·  02-20 16:32
Sino Biopharmaceutical Stock Rises 1.8% in Hong Kong
BRIEF-Sino Biopharmaceutical Says NMPA Approved Benmelstobart Injection For Marketing
Reuters  ·  02-16
BRIEF-Sino Biopharmaceutical Says NMPA Approved Benmelstobart Injection For Marketing
Sino Biopharm (1177) Announces Approval of Benmelstobart Injection for NSCLC Maintenance Therapy
Bulletin Express  ·  02-16
Sino Biopharm (1177) Announces Approval of Benmelstobart Injection for NSCLC Maintenance Therapy
SINO BIOPHARM's Innovative Drug Bemusubain Injection Gains Approval for New NSCLC Indication
Stock News  ·  02-16
SINO BIOPHARM's Innovative Drug Bemusubain Injection Gains Approval for New NSCLC Indication
Sino Biopharmaceutical - Approval for Marketing of Benmelstobart Injection by China's Nmpa
THOMSON REUTERS  ·  02-16
Sino Biopharmaceutical - Approval for Marketing of Benmelstobart Injection by China's Nmpa
Sino Biopharmaceutical Gains NMPA Approval for Benmelstobart in Stage III NSCLC Maintenance Therapy
Reuters  ·  02-16
Sino Biopharmaceutical Gains NMPA Approval for Benmelstobart in Stage III NSCLC Maintenance Therapy
Sino Biopharmaceutical Stock Slips 0.9% in Hong Kong, Underperforms Competitors
Dow Jones  ·  02-13
Sino Biopharmaceutical Stock Slips 0.9% in Hong Kong, Underperforms Competitors
Sino Biopharmaceutical Stock Sheds 3.7% in Hong Kong, Underperforms Competitors
Dow Jones  ·  02-12
Sino Biopharmaceutical Stock Sheds 3.7% in Hong Kong, Underperforms Competitors
Bank of America Securities Reaffirms Buy Rating on Sino Biopharm Following Positive Progress on Two Drug Candidates
Stock News  ·  02-12
Bank of America Securities Reaffirms Buy Rating on Sino Biopharm Following Positive Progress on Two Drug Candidates
Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation
Stock News  ·  02-12
Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation
Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug
Stock Track  ·  02-10
Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug
Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug
MT Newswires Live  ·  02-10
Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug
Chinese Pharmaceutical Firm Completes Patient Enrollment for Phase III Trial of HER2-Targeting Drug
Stock News  ·  02-10
Chinese Pharmaceutical Firm Completes Patient Enrollment for Phase III Trial of HER2-Targeting Drug
Sino Biopharm (1177) Completes Phase III Enrollment for TQB2102 “HER2 Bispecific ADC” in HER2-Low Breast Cancer
Bulletin Express  ·  02-10
Sino Biopharm (1177) Completes Phase III Enrollment for TQB2102 “HER2 Bispecific ADC” in HER2-Low Breast Cancer
Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer
Reuters  ·  02-10
Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer
Sino Biopharmaceutical Stock Rallies 1.9% in Hong Kong, Outperforms Competitors
Dow Jones  ·  02-09
Sino Biopharmaceutical Stock Rallies 1.9% in Hong Kong, Outperforms Competitors
BUZZ-Sino Biopharm climbs most in five weeks on cancer drug development progress
Reuters  ·  02-09
BUZZ-Sino Biopharm climbs most in five weeks on cancer drug development progress
SINO BIOPHARM (01177): Patient Enrollment Completed for Phase III Trial of Claudiximab "CLDN18.2 ADC"
Stock News  ·  02-09
SINO BIOPHARM (01177): Patient Enrollment Completed for Phase III Trial of Claudiximab "CLDN18.2 ADC"
Sino Biopharmaceutical (1177) Announces Completion of Phase III Enrollment for Tecotabart Vedotin “CLDN18.2 ADC”
Bulletin Express  ·  02-09
Sino Biopharmaceutical (1177) Announces Completion of Phase III Enrollment for Tecotabart Vedotin “CLDN18.2 ADC”
Sino Biopharmaceutical Completes Phase III Enrollment for Tecotabart Vedotin in Gastric Cancer
Reuters  ·  02-09
Sino Biopharmaceutical Completes Phase III Enrollment for Tecotabart Vedotin in Gastric Cancer
No data available

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
Issue price:
--